Literature DB >> 9951978

Clinical implications of penicillin and ceftriaxone resistance among children with pneumococcal bacteremia.

M Silverstein1, R Bachur, M B Harper.   

Abstract

OBJECTIVES: To determine whether reduced penicillin or ceftriaxone susceptibility affects clinical presentation and outcome in children with pneumococcal bacteremia.
DESIGN: Retrospective review of patients with Streptococcus pneumoniae bacteremia.
RESULTS: We reviewed 922 cases of pneumococcal bacteremia. Of 744 isolates with known penicillin (PCN) susceptibilities 56 were PCN-nonsusceptible. The majority displayed intermediate resistance; 14 of 730 isolates with known ceftriaxone (CTX) susceptibilities were CTX-nonsusceptible. Neither the PCN- nor the CTX-nonsusceptible cohort displayed a difference from its susceptible counterpart in temperature, respiratory rate or white blood cell count on initial patient evaluation, although trend suggested they were more often admitted at the initial visit. At follow-up only children treated initially with antibiotic were evaluated. Children with PCN-nonsusceptible isolates were no more likely to be febrile than those with PCN-susceptible isolates (28% vs. 25%, P = 0.61) and were no more likely to have a positive repeat blood culture (0% vs. 1%, P = 0.59) or a new focal infection (10% vs. 6%, P = 0.79). Data concerning CTX-nonsusceptible organisms were limited by the low number of such isolates. Although patients with CTX-nonsusceptible pneumococci were more likely to be febrile at follow-up than those with CTX-susceptible organisms (67% vs. 24%, P = 0.04), we were unable to demonstrate a significant difference for other endpoints.
CONCLUSIONS: Reduced antibiotic susceptibility does not alter the clinical presentation of pneumococcal bacteremia. With current practice intermediate resistance to PCN is of little clinical significance in nonmeningitic systemic pneumococcal infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9951978     DOI: 10.1097/00006454-199901000-00010

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  7 in total

1.  Two-year surveillance of antibiotic resistance in Streptococcus pneumoniae in four African cities.

Authors:  M Benbachir; S Benredjeb; C S Boye; M Dosso; H Belabbes; A Kamoun; O Kaire; N Elmdaghri
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.

Authors:  Seong-Ho Choi; Jin-Won Chung; Heungsup Sung; Mi-Na Kim; Sung-Han Kim; Sang-Oh Lee; Yang Soo Kim; Jun Hee Woo; Sang-Ho Choi
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

3.  Phenotypic and genotypic characterization of invasive Streptococcus pneumoniae clinical isolates.

Authors:  Abdulaziz M Al-Swailem; Ashraf A Kadry; Soliman I Fouda; Atef M Shibl; Omar H Shair
Journal:  Curr Ther Res Clin Exp       Date:  2004-09

4.  Approach to the febrile child: A challenge bridging the gap between the literature and clinical practice.

Authors:  Jean-Bernard Girodias; Benoit Bailey
Journal:  Paediatr Child Health       Date:  2003-02       Impact factor: 2.253

5.  Bacteremia in children at the University Hospital in Riyadh, Saudi Arabia.

Authors:  Fahad Abdullah Al-Zamil
Journal:  World J Pediatr       Date:  2008-05       Impact factor: 2.764

6.  Pneumococcal bacteremia in children: an 8-year review in two hospitals in Barcelona.

Authors:  A Pérez; P Sala; M Giménez; M Sierra; A Esteve; A Alonso; M Quesada; F Raspall; V Ausina; C Rodrigo
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-08-18       Impact factor: 3.267

7.  Reference group choice and antibiotic resistance outcomes.

Authors:  Keith S Kaye; John J Engemann; Essy Mozaffari; Yehuda Carmeli
Journal:  Emerg Infect Dis       Date:  2004-06       Impact factor: 6.883

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.